Welcome
Support Centre
10 January 2009 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Determining if ingestion of silybum marianum (milk thistle) influences the metabolisation of indinavir in healthy subjects: a randomised controlled phase I study
ISRCTN ISRCTN78545137
ClinicalTrials.gov identifier
Public title Determining if ingestion of silybum marianum (milk thistle) influences the metabolisation of indinavir in healthy subjects: a randomised controlled phase I study
Scientific title
Acronym N/A
Serial number at source N/A
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Canada
Disease/condition/study domain Drug interactions
Participants - inclusion criteria 1. Documented Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot results negative for Human Immunodeficiency Virus (HIV)
2. Aged 18 - 35 years
3. Sex male, race Caucasian, and normal findings of laboratory and physical examinations
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/2003
Anticipated end date 31/12/2005
Status of trial Completed
Patient information material
Target number of participants 24
Interventions Milk thistle (silybum marianum) and indinavir.

Twenty-four healthy male participants: All individuals will receive a HIV test and Liver Function Tests (LFTs - aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma-glutamyl transferase [GGT]) to exclude HIV and liver disease, and also a Complete Blood Count (CBC).

Subjects are requested to discontinue all medications, alcohol, caffeine, nicotine and other known CYP 3A4 inducers and inhibitors. Informed consent will be obtained from all participants.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Ontario HIV Treatment Network (Canada)
Trial website
Publications Results in http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15666173
Contact name Mr  Edward  Mills
  Address Director of Research, Canadian College of Naturopathic Medicine
1255 Sheppard Ave East
  City/town North York, Ontario
  Zip/Postcode M2K 1E2
  Country Canada
  Tel +1 416 498 1255 ext 324
  Fax +1 416 498 1643
  Email emills@ccnm.edu
Sponsor Ontario HIV Treatment Network
  Address 1300 Yonge Street
Suite 308
  City/town Toronto, Ontario
  Zip/Postcode M4T 1X3
  Country Canada
  Tel +1 416 642 6486<BR/>Toll Free: +1 877 743 6486
  Fax +1 416 640 4245
  Email info@ohtn.on.ca
Date applied 06/11/2002
Last edited 09/10/2007
Date ISRCTN assigned 06/11/2002
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central